R & S Northeast

Kremers Urban Pharmaceuticals, a subsidiary of Lannett Company, has been dedicated to providing high-quality, affordable generic pharmaceutical products for over 75 years. With a focus on patient care, the company manufactures over 100 unique pharmaceutical product families across a wide range of therapeutic areas, continually striving for the highest quality standards in its offerings. The company recently achieved a significant milestone with the FDA approval of Mycophenolate Mofetil for Oral Suspension, marking a new dosage form for the organization. This accomplishment highlights Kremers Urban's commitment to innovation and excellence in pharmaceutical development, ensuring that patients receive the medications they depend on. Generated from the website

Lannett Company develops, manufactures, packages, markets and distributes pharmaceutical products sold under generic chemical names. The company uses its resources to research and develop projects that include new generic product offerings. Lannett's manufacturing facility consists of more than 31,000 square feet on nearly 3.5 acres owned by the company. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private-label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups and health maintenance organizations. Lannett Company is headquartered in Philadelphia.

Founded in 1946, URL Pharma Inc. is a research and technology-driven, proprietary-branded pharmaceutical business. Formed as United Research Laboratories, it gained its current name in 2008. URL Pharma Inc.'s research focuses on developing scientific and medical innovations for existing compounds to serve unmet medical needs. With more than 60 years of operating history, it has a diversified product portfolio, including a deep, mid-to-late-stage branded product and technology pipeline. The company markets four branded prescription medications. URL Pharma Inc. successfully commercialized its first internally developed branded product in 2006. The company s overall Research and Development (R&D) budget for 2008 expectedly exceeded $60 million.